Description
The debate highlighted that mitochondrial transfer could be therapeutic, but raised concerns about whether mitochondria from AD or other neurodegenerative disease contexts retain dysfunction. This fundamental question determines whether enhancing transfer is beneficial or harmful.
Source: Debate session sess_sda-2026-04-01-gap-v2-89432b95 (Analysis: sda-2026-04-01-gap-v2-89432b95)
Resolution criteria
Resolved when co-culture experiments demonstrate that mitochondria isolated from AD-patient or alpha-syn-overexpressing astrocytes and transferred to neurons result in: (a) mitochondrial membrane potential <=10% below healthy-donor transfer controls (TMRE assay), (b) ROS production <=1.5x healthy controls (MitoSOX), and © ATP output within 25% of healthy-donor controls (Seahorse XF24). Alternatively, >=2-fold increased neurotoxicity with diseased mitochondria qualifies as negative evidence. Transfer efficiency must be confirmed >=80% by CytoID or MitoTracker. Deliverable: raw Seahorse data in Zenodo; SciDEX KG edge astrocyte_mitochondria->neuronal_health tagged ‘quality_characterised’.